Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
03/1999
03/11/1999WO1999011782A1 T-cell membrane protein (tirc7), peptides and antibodies derived therefrom and uses thereof
03/11/1999WO1999011753A1 SpoOJ2 OF STAPHYLOCOCCUS AUREUS
03/11/1999WO1999011649A2 Parp inhibitors, pharmaceutical compositions comprising same, and methods of using same
03/11/1999WO1999011283A1 Method for treating a subject suffering from conditions associated with an extracellular zinc sphingomyelinase
03/11/1999WO1999011263A1 Combination therapy comprising amlodipine and a statin compound
03/11/1999WO1999011260A1 Combination therapy comprising atorvastatin and an antihypertensive agent
03/11/1999WO1999011258A1 Lymphocyte function antigen-1 antagonists
03/11/1999WO1999011257A1 Improved compositions and methods for the control of smoking
03/11/1999WO1999011242A1 Oral liposomal delivery system
03/11/1999WO1998057990A3 Methods and compositions for treating abnormal cell growth related to unwanted guanine nucleotide exchange factor activity
03/11/1999WO1998056360A3 Film-coated tablet for improved upper gastrointestinal tract safety
03/11/1999WO1998050064A3 Adhesion prevention and an endoscopic insufflation system therefor
03/11/1999DE19738855A1 Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht Transdermal therapeutic system with contact adhesive reservoir layer and unidirectional elastic backing
03/11/1999DE19738604A1 Use of Na<+>/H<+> exchange inhibitors
03/11/1999CA2303200A1 Oral liposomal delivery system
03/11/1999CA2302248A1 Improved compositions and methods for the control of smoking
03/11/1999CA2302168A1 Method for treating a subject suffering from conditions associated with an extracellular zinc sphingomyelinase
03/11/1999CA2296723A1 Combination therapy comprising atorvastatin and an antihypertensive agent
03/11/1999CA2294074A1 Parp inhibitors, pharmaceutical compositions comprising same, and methods of using same
03/10/1999EP0900848A2 MecB polynucleotides and polypeptides from the Clpc ATPase family of Stapyloccoccus aureus
03/10/1999EP0900847A2 Phosphoribosyl transferase from Staphylococcus aureus
03/10/1999EP0900846A2 Nucleic acid encoding Streptococcus pneumoniae response regulator
03/10/1999EP0900844A2 Membrane protein of Staphylococcus aureus
03/10/1999EP0900843A2 FfH polypeptide from Streptococcus
03/10/1999EP0900568A2 AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy
03/10/1999EP0900567A2 Quinazoline-4-one AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy
03/10/1999EP0900384A2 Novel treatment
03/10/1999EP0900379A1 RECEPTOR FOR UNDERIVATIZED, AQUEOUS SOLUBLE $g(b)(1-3)-GLUCAN
03/10/1999EP0900275A1 Methods and reagents for modulating apoptosis
03/10/1999EP0900272A2 Tumor necrosis factor alpha convertase
03/10/1999EP0900231A1 Flea protease proteins, nucleic acid molecules, and uses thereof
03/10/1999EP0900197A1 Beta-thiopropionyl-aminoacid derivatives and their use as beta-lactamase inhibitors
03/10/1999EP0900086A1 Enhancement of sleep with a growth hormone secretagogue
03/10/1999EP0900007A1 Low ph acidic compositions
03/10/1999EP0505357B1 Method for antibody targeting of diagnostic or therapeutic agents
03/10/1999CN1210459A Sustained delivery of active agent using an implantable system
03/10/1999CN1209995A The use of inhibitors of sodium-hydrogen exchanger for production of medicaement for decreaing undesired effects of substances on heart
03/10/1999CN1209994A Use of inhibitors of sodium-hyfrogen exchanger for production of pharmaceutical for treatment of disorders which are caused by protozoa
03/10/1999CA2243670A1 Novel histidine kinase
03/09/1999US5880267 Trophinin and trophinin-assisting protein agonists, antibodies and antagonists
03/09/1999US5880132 Tachykinin antagonist and an opioid analgesic effective at treating pain or nociception
03/09/1999US5880124 For treatment of hypotension
03/09/1999US5880100 Method for inhibiting binding of human lens cells
03/09/1999US5879908 CRFG-1a, a target and marker for chronic renal failure
03/09/1999US5879893 Hybridization method for detecting polynucleotides coding for signal transduction inhibitor protein in body fluids and tissue samples; treatment of alzheimer's disease and cancer
03/09/1999US5879690 Increasing muscle tone in subcutaneous muscle tissue
03/09/1999US5879688 Treatment of skin disorders, wrinkling, aging
03/09/1999CA2243656A1 Response regulator
03/04/1999WO1999010529A1 Methods for analyzing ltc4 synthase polymorphisms and diagnostic use
03/04/1999WO1999010525A1 A method of treating cancer
03/04/1999WO1999010523A1 A method of treating cancer
03/04/1999WO1999010502A1 Human nucleotide pyrophosphohydrolase
03/04/1999WO1999010492A1 Adipocyte-specific protein homologs
03/04/1999WO1999010480A2 New tissue-specific calpaines, their production and their use
03/04/1999WO1999010012A1 NOVEL priA
03/04/1999WO1999010009A1 A process for inhibiting complement activation via the alternative pathway
03/04/1999WO1999010007A1 Methods and compositions for enhanced wound healing
03/04/1999WO1999010003A1 Androgen activity antagonists as therapies for anorexia, anorexia nervosa, and disorders characterized by a pathologically underweight condition
03/04/1999WO1999010000A1 Combined preparations for treating upper gastrointestinal tract distress
03/04/1999WO1999009998A1 Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases
03/04/1999WO1999009997A1 Edta and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections
03/04/1999WO1999009992A1 Neovascularization promoters
03/04/1999WO1999009987A1 Method for treating premenstrual or late luteal phase syndrome
03/04/1999WO1999009982A1 Prevention of adhesions and excessive scar formation using angiogenesis inhibitors
03/04/1999WO1999009980A1 Method for treating pain
03/04/1999WO1999009978A1 Method for treatment of non-rheumatoid athritis
03/04/1999WO1999009973A1 Pharmacologic drug combination in vagal-induced asystole
03/04/1999WO1999009967A2 Cholesterol-lowering therapy
03/04/1999WO1999009964A2 Pharmaceutical composition containing clindamycin and clotrimazol for treating vaginal infections
03/04/1999WO1999009957A1 Pharmaceutical composition for combination of piperidinoalkanol-decongestant
03/04/1999WO1999009954A1 Non-steroidal antiinflammatory drug formulations for topical application to the skin
03/04/1999WO1999009953A1 Glucose-containing preparation
03/04/1999WO1998056408A3 Inhibitors of microbial adherence or invasion as therapeutic agents and broad-spectrum enhancers of antibiotic therapy
03/04/1999WO1998056407A3 Fibronectin antagonists as therapeutic agents and broad-spectrum enhancers of antibiotic therapy
03/04/1999DE19737348A1 Neue pharmazeutische Zusammensetzung New pharmaceutical composition
03/04/1999DE19737105A1 Neue gewebsspezifische Calpaine, ihre Herstellung und Verwendung New tissue-specific calpain, their preparation and use
03/04/1999CA2302504A1 Method for treating pain
03/04/1999CA2302317A1 A process for inhibiting complement activation via the alternative pathway
03/04/1999CA2302023A1 Angiogenesis promoter
03/04/1999CA2301880A1 A method of treating cancer
03/04/1999CA2301877A1 A method of treating cancer
03/04/1999CA2301815A1 New tissue-specific calpaines, their production and their use
03/04/1999CA2301780A1 Androgen activity antagonists as therapies for anorexia, anorexia nervosa, and disorders characterized by a pathologically underweight condition
03/04/1999CA2301661A1 Human nucleotide pyrophosphohydrolase
03/04/1999CA2301660A1 Adipocyte-specific protein homologs
03/04/1999CA2301586A1 Method for treatment of non-rheumatoid arthritis
03/04/1999CA2300165A1 Cholesterol-lowering therapy
03/04/1999CA2300146A1 Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases
03/04/1999CA2298979A1 Method for treating premenstrual or late luteal phase syndrome
03/04/1999CA2246633A1 The use of inhibitors of the sodium-hydrogen exchanger for the production of a medicament for decreasing undesired effects of substances on the heart
03/04/1999CA2242260A1 Spo0j1
03/04/1999CA2242258A1 Novel compounds
03/04/1999CA2242254A1 Novel tig
03/03/1999EP0899339A1 The Chlamydia trachomatis Glutamyl-tRNAGln amidotransferase subunit ratB
03/03/1999EP0899338A2 Seryl tRNA synthetase of Streptococcus pneumoniae (serS)
03/03/1999EP0899337A2 FtsY polynucleotides and polypeptides of Stapyloccoccus aureus belonging to the signal recognition protein family
03/03/1999EP0899335A2 MurB gene from Staphylococcus aureus
03/03/1999EP0899334A2 FtsZ polypeptides from Streptococcus pneumoniae
03/03/1999EP0899333A2 Ribonucleotide reductase gene nrdD from Staphylococcus aureus
03/03/1999EP0899332A2 The G-protein coupled receptor HFIAO41
1 ... 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 ... 1151